Suppr超能文献

终末期肾病中维拉帕米所致低血压:葡萄糖酸钙的作用

Verapamil-Induced Hypotension in End-Stage Renal Disease: The Role of Calcium Gluconate.

作者信息

Kaisbain Neerusha, Lim Wei Juan, Kaisbain Vareeja

机构信息

Cardiology, Hospital Queen Elizabeth II, Sabah, MYS.

Cardiology, National Heart Institute (IJN), Kuala Lumpur, MYS.

出版信息

Cureus. 2023 Jan 4;15(1):e33341. doi: 10.7759/cureus.33341. eCollection 2023 Jan.

Abstract

Verapamil is a useful drug in supraventricular tachycardias, atrial flutters, and fibrillations. However, its usage is accompanied by an undesirable side effect of hypotension. This limits its usage in patients where even the slightest reduction of blood pressure for a brief period may prove detrimental, e.g., in patients with critical coronary artery disease. Intravenous calcium given as pretreatment to verapamil prevented verapamil-induced hypotension. Its usage after hypotension restored the blood pressure to its baseline level. All these occur without the loss of the antiarrhythmic effect of verapamil. Furthermore, the pharmacokinetics of verapamil is unaltered in patients with chronic kidney disease. Thus, no dosage adjustment is required in this population. Here we describe a case of verapamil-induced hypotension in a patient with end-stage renal failure, which was reverted with intravenous calcium administration without altering the atrioventricular blockade effect of verapamil.

摘要

维拉帕米是治疗室上性心动过速、心房扑动和颤动的有效药物。然而,其使用伴随着低血压这一不良副作用。这限制了它在即使短期内血压稍有下降也可能有害的患者中的应用,例如患有严重冠状动脉疾病的患者。静脉注射钙作为维拉帕米的预处理可预防维拉帕米引起的低血压。在出现低血压后使用它可使血压恢复到基线水平。所有这些情况发生时,维拉帕米的抗心律失常作用并未丧失。此外,慢性肾病患者中维拉帕米的药代动力学未改变。因此,该人群无需调整剂量。在此,我们描述了一例终末期肾衰竭患者发生维拉帕米诱导的低血压,通过静脉注射钙剂得以纠正,且未改变维拉帕米的房室传导阻滞作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecc5/9896430/97f46232da04/cureus-0015-00000033341-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验